Ahead of a campaign trip to New Hampshire, South Bend Mayor Pete Buttigieg released a plan to expand mental health care services and fight addiction, with the goal of preventing 1 million deaths over the next nine years.
The plan would strengthen enforcement of “parity” requirements between mental health care and other services and substantially reduce the number of people incarcerated due to mental illness and addiction.
The policy aims to prevent 1 million “deaths of despair” by 2028, including deaths due to drugs, alcohol and suicide. The plan would also ensure that at least 75% of people who need mental health care and addiction treatment get the care they need by the end of Buttigieg’s first term in office.
Why does e-cigarette maker Juul advertise its product on TV when cigarette ads are banned? The short answer: Because it can.
For nearly 50 years, cigarette advertising has been banned from TV and radio. But electronic cigarettes — those battery-operated devices that often resemble oversized USB flash drives with flavored nicotine “pods” that clip in on the end — aren’t addressed in the law.
Since launching its product in 2015, Juul Labs, based in San Francisco, have come to dominate the e-cigarette market, now accounting for 75 percent of e-cig sales at convenience stores and mass retail outlets, according to Bonnie Herzog, a senior analyst at Wells Fargo Securities. Until recently, TV ads haven’t played a role in Juul’s marketing, which relied primarily on social media.
An analysis of three previous studies of children and young adults with attention-deficit hyperactivity disorder (ADHD) quantifies for the first time the extent to which stimulant treatment reduces the development of mood disorders, school problems, conduct disorders, substance use disorders and other problems. The study led by Massachusetts General Hospital investigators is being published online in the Journal of Adolescent Health.
“Our study documents that early treatment with stimulant medication has very strong protective effects against the development of serious, ADHD-associated functional complications like mood and anxiety disorders, conduct and oppositional defiant disorder, addictions, driving impairments and academic failure,” says Joseph Biederman, MD, chief of the Pediatric Psychopharmacology and Adult ADHD Program at MGH and MassGeneral Hospital for Children. “In quantifying the improvement seen with stimulant treatment, it measures its potency in mitigating specific functional outcomes.”
Previous studies of stimulant treatment for ADHD have had limitations, such as only investigating outcomes in boys or not calculating the magnitude of the protective effects of treatment. The current study determined the number needed to treat (NNT) statistic, often used to show the effectiveness of an intervention. As the title indicates, NNT reflects the number of individuals receiving a medication or other treatment needed to prevent a specific unwanted outcome — the lower the NNT, the more effective the treatment.
New research conducted at OHSU in Portland, Oregon, identifies a gene that could provide a new target for developing medication to prevent and treat alcoholism.
Scientists at the Oregon National Primate Research Center at OHSU discovered a gene that had lower expression in the brains of nonhuman primates that voluntarily consumed heavy amounts of alcohol compared with those that drank less.
Furthermore, the research team unraveled a link between alcohol and how it modulates the levels of activity of this particular gene. Researchers discovered that when they increased the levels of the gene encoded protein in mice, they reduced alcohol consumption by almost 50 percent without affecting the total amount of fluid consumed or their overall well-being.
Whether they use marijuana for recreational or medicinal purposes, people can develop withdrawal symptoms when they stop using it.
Marijuana, or cannabis, is the “most commonly used illicit drug in the United States,” according to the Centers for Disease Control and Prevention (CDC).
In recent years, more states have legalized the recreational and medicinal use of marijuana. However, based on a 2018 survey from Washington State, legalization does not seem to have significantly increased marijuana use. That said, marijuana use has been gaining a lot of attention.
Growing up, I had the picture-perfect family. I lived in a beautiful home in the suburbs of Detroit with my parents and younger brother. I had every opportunity in the world, attended private schools, and even made it onto the honor roll. I was involved in dance, theater, and many of the school sports teams.
Beneath the surface, however, I always felt a lot of pressure to be perfect.
I was the first of 12 grandchildren, and this led to me feeling that I had to be the best at everything I did, which gave me terrible anxiety from the early age of 5.
When public health officials get wind of an outbreak of Hepatitis A or influenza, they spring into action with public awareness campaigns, monitoring and outreach. But should they be acting with equal urgency when it comes to childhood trauma?
A new study published in the Journal of the American Medical Association suggests the answer should be yes. It shows how the effects of childhood trauma persist and are linked to mental illness and addiction in adulthood. And, researchers say, it suggests that it might be more effective to approach trauma as a public health crisis than to limit treatment to individuals.
The study drew on the experiences of participants from the Great Smoky Mountains Study, which followed 1,420 children from mostly rural parts of western North Carolina, over a period of 22 years. They were interviewed annually during their childhood, then four additional times during adulthood.
As marijuana legalization builds momentum across the United States — with Michigan becoming the latest state to allow recreational use by adults — researchers are warning that more studies are needed on the long-term effects of chronic pot smoking on the human brain.
Marijuana is the most commonly used illicit drug in the United States, but little is known about its effect on health or how addictive it is.
According to a 2017 poll conducted by Marist College and Yahoo News, more than half of American adults have tried marijuana at least once in their lives, and nearly 55 million of them, or 22 percent, say they use it currently. Close to 35 million are what the survey calls “regular users,” people who say they use marijuana at least once or twice a month.
The tech sector is built on bright minds developing new solutions to create economic or social impact. This fast-paced industry has high stakes, which require people to meet even higher expectations. Many individuals within the sector — especially startup founders — have small teams (meaning each person serves in multiple roles), work long hours, second jobs or are still in school and constantly worry about “making it.”
At the DMZ, we see that many entrepreneurs are still not talking openly about their mental well-being. And these challenges aren’t special to our organization. Mental health concerns in tech entrepreneurship are often referred to as “founder’s blues.” Between 2011 and 2017, founder’s blues has contributed to a number of high-profile suicides in the startup world, including Aaron Swartz, co-founder of Reddit.
Researchers from the University of California found that 72% of entrepreneurs surveyed self-reported mental health concerns. And about 49% disclosed they deal with ADD, ADHD, bipolar disorder, addiction, depression or anxiety. These figures were described as “significantly higher” than non-entrepreneurs.
Watching as a video game ensnares their child, many a parent has grumbled about “digital heroin,” likening the flashing images to one of the world’s most addictive substances.
Now, they may have backup: The World Health Organization is set to announce “gaming disorder” as a new mental health condition to be included in the 11th edition of its International Classification of Diseases, set to release Monday.
“I’m not creating a precedent,” said Dr. Vladimir Poznyak, a member of WHO’s Department of Mental Health and Substance Abuse, which proposed the new diagnosis to WHO’s decision-making body, the World Health Assembly. Instead, he said, WHO has followed “the trends, the developments, which have taken place in populations and in the professional field.”